Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Skin Neoplasms
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Neoplasms
Hierarchy View
Subtype Terms (4)
Mastocytosis, Cutaneous
4 drugs (3 approved, 1 experimental)
Phase 2 Indicated Drugs (66)
anti-gp 100:154 tcell receptor peripheral blood lymphocyte
autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes
autologous anti-gp 100:154-162 t-cell receptor gene-engineered tumor infiltrating lymphocytes
autologous anti-mart-1 f5 t-cell receptor
autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes
Other Experimental Indicated Drugs (13)
Organization Involved with Phase 4 Indications (15)
Organization Involved with Phase 3 Indications (18)
Organization Involved with Phase 2 Indications (94)
British Columbia Cancer Agency
Canadian Institutes of Health Research (CIHR)
Cancer Biotherapy Research Group
Cancer Immunotherapy Trials Network
Cantonal Hospital of St. Gallen
Chao Family Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Icahn School of Medicine at Mount Sinai
Istituto Nazionale per lo Studio e la Cura dei Tumori
Laser and Skin Surgery Center of New York
Ligue contre le cancer, France
Ludwig Institute for Cancer Research
Manuel Fajardo Clinical Surgical University Hospital
Medical University of South Carolina
National Cancer Institute, France
Oregon Health and Science University
Siller Medical T/A Central Brisbane Dermatology
State University of New York, Buffalo
Organization Involved with Phase 1 Indications (28)
Organization Involved with Other Experimental Indications (23)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
